Efficacy and safety of oral anticoagulants according to kidney function among patients with atrial fibrillation.
Casper BindingPaul F BlancheGregory Yoke Hong LipAnne-Lise KamperChristina J Y LeeLaila StaerkGunnar Hilmar GislasonChristian Torp-PedersenJonas Bjerring OlesenAnders Nissen BondePublished in: European heart journal. Cardiovascular pharmacotherapy (2024)
Overall, we found no differences regarding the risk of stroke/TE, but apixaban was associated with a 21% lower relative risk of major bleeding compared to VKA. This risk reduction was even greater when comparing apixaban and rivaroxaban among patients with eGFR 15-30 mL/min/1.73m2, and when comparing apixaban to dabigatran and rivaroxaban among patients with eGFR 30-49 mL/min/1.73m2.